07/17/2024 4:10 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/10/2024 3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/08/2024 6:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/02/2024 6:44 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2024 6:45 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2024 6:45 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2024 6:45 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
06/27/2024 8:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/25/2024 6:45 PM | Ligand Pharmaceuticals (Issuer) Sabba Stephen L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:25 PM | Aryeh Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:26 PM | Gray Nancy Ryan (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:26 PM | Haas Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:26 PM | KOZARICH JOHN W (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:27 PM | LAMATTINA JOHN L (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 8:27 PM | Ligand Pharmaceuticals (Issuer) Zimmermann Martine (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2024 4:14 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/17/2024 6:59 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/17/2024 7:00 PM | Gray Nancy Ryan (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/17/2024 4:45 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024 4:39 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024 6:34 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/15/2024 5:01 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024 1:45 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144/A | |
05/14/2024 6:42 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024 5:14 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024 4:32 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/09/2024 5:03 PM | Gray Nancy Ryan (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024 5:06 PM | Ligand Pharmaceuticals (Subject) Reardon Andrew (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024 3:11 PM | Ligand Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2024 6:36 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 5:07 PM | Aryeh Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/26/2024 5:35 PM | KOZARICH JOHN W (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/27/2024 4:47 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/07/2024 12:27 PM | Ligand Pharmaceuticals (Issuer) Sabba Stephen L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/06/2024 4:28 PM | Aryeh Jason (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2024 5:12 PM | Ligand Pharmaceuticals (Subject) Sabba Stephen L (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024 5:49 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 5:50 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 5:50 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 5:50 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 3:49 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144/A | |
This TSLA short trade is on a nine win hot streak (Ad) Most Tesla Shareholders are disappointed in the stock's performance in 2024.
Year to date, it's down 30%...
And things don’t seem to be getting better.
That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity…
In fact, he has not lost a single trade on Tesla this year.
As of this mailing he’s 9 for 9 with incredible wins under his belt.
Just see for yourself.![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8566&Placement=NativeDisplay&Source=NativeDisplay) But I can promise that you’ll see all the details for yourself here. |
02/29/2024 3:16 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/28/2024 5:05 PM | Gray Nancy Ryan (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024 4:43 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/27/2024 6:24 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/16/2024 7:10 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 7:10 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 7:10 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/16/2024 7:10 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2024 5:26 AM | Ligand Pharmaceuticals (Subject) MACQUARIE GROUP LTD (Filed by)
| Form SC 13G | |
02/13/2024 2:39 PM | JANUS HENDERSON GROUP PLC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/12/2024 6:42 PM | GOLDMAN SACHS GROUP INC (Filed by) GOLDMAN SACHS GROUP INC (Filed by) Ligand Pharmaceuticals (Subject)
| Form SC 13G | |
01/22/2024 1:03 PM | BlackRock Inc. (Filed by) Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/04/2024 3:07 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:07 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/06/2023 2:27 PM | Korenberg Matthew E (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/06/2023 2:27 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/01/2023 7:25 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/18/2023 8:03 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/03/2023 3:36 PM | Espinoza Octavio (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/27/2023 7:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/26/2023 3:41 PM | Ligand Pharmaceuticals (Issuer) Zimmermann Martine (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/25/2023 5:12 PM | Ligand Pharmaceuticals (Issuer) Zimmermann Martine (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/25/2023 3:44 PM | Davis Todd C (Reporting) Ligand Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/18/2023 4:26 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/14/2023 3:20 PM | Ligand Pharmaceuticals (Issuer) Reardon Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |